文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Familial hypercholesterolemia in Southeast and East Asia.

作者信息

Jackson Candace L, Zordok Magdi, Kullo Iftikhar J

机构信息

Department of Medicine, Mayo Clinic, Rochester, MN USA.

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN USA.

出版信息

Am J Prev Cardiol. 2021 Feb 12;6:100157. doi: 10.1016/j.ajpc.2021.100157. eCollection 2021 Jun.


DOI:10.1016/j.ajpc.2021.100157
PMID:34327494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8315601/
Abstract

Familial hypercholesterolemia (FH) is a relatively common autosomal dominant disorder associated with a significantly increased risk of coronary heart disease (CHD). Most (~85-90%) cases are due to pathogenic variants in the LDL-receptor gene (), while the remaining are due to pathogenic variants in the apolipoprotein B () and proprotein convertase subtilisin/kexin type 9 () genes, though the proportion may vary depending on geographic location. Even though at least a quarter of the world's FH population lives in Southeast and East Asia, there are substantial gaps in knowledge regarding the epidemiology of FH due to low awareness, the absence of national screening programs, and limited availability of genetic testing. In this review, we discuss the most recent and relevant information available related to diagnostic criteria, prevalence, awareness, clinical characteristics, genetic epidemiology, and treatment in the FH population of Southeast and East Asia. Increasing awareness and improving the diagnosis and management of FH will reduce the burden of premature CHD in these regions of the world.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3c/8315601/b2fa8d7e14cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3c/8315601/b2fa8d7e14cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec3c/8315601/b2fa8d7e14cb/gr1.jpg

相似文献

[1]
Familial hypercholesterolemia in Southeast and East Asia.

Am J Prev Cardiol. 2021-2-12

[2]
Genetic Diagnosis of Familial Hypercholesterolemia in Asia.

Front Genet. 2020-7-24

[3]
Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation.

Atherosclerosis. 2014-9

[4]
Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia.

Lipids Health Dis. 2023-10-18

[5]
Cascade Screening for Familial Hypercholesterolemia (FH).

PLoS Curr. 2011-5-23

[6]
Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.

JACC Asia. 2021-4-21

[7]
Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study.

JMIR Res Protoc. 2023-6-2

[8]
Portuguese Familial Hypercholesterolemia Study: presentation of the study and preliminary results.

Rev Port Cardiol. 2006-11

[9]
Genetic polymorphisms in LDLR, APOB, PCSK9 and other lipid related genes associated with familial hypercholesterolemia in Malaysia.

PLoS One. 2013-4-8

[10]
Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.

Atherosclerosis. 2016-8-26

引用本文的文献

[1]
Design of lipid nanoparticle (LNP) containing genetic material CRISPR/Cas9 for familial hypercholesterolemia.

Narra J. 2025-4

[2]
Dyslipidaemia among children and adolescents in Pakistan: a five-year retrospective cohort study based on laboratory data.

Lipids Health Dis. 2025-3-22

[3]
Prevalence of genetically diagnosed familial hypercholesterolemia in Vietnamese patients with premature acute myocardial infarction.

Medicine (Baltimore). 2024-9-27

[4]
Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.

Am J Case Rep. 2023-4-27

[5]
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2).

BMC Med. 2023-2-28

[6]
The alasian alth and Welleing ssessmen (MyHEBAT) Study Protocol: An Initiation of a National Registry for Extended Cardiovascular Risk Evaluation in the Community.

Int J Environ Res Public Health. 2022-9-19

[7]
The Association Between Long Working Hours of Parents and Dyslipidemia in Their Children.

Front Public Health. 2022

[8]
The Progression of Treatment for Refractory Hypercholesterolemia: Focus on the Prospect of Gene Therapy.

Front Genet. 2022-6-9

[9]
Asian Pacific Society of Cardiology Consensus Recommendations on Dyslipidaemia.

Eur Cardiol. 2021-12-9

本文引用的文献

[1]
The first Japanese cases of familial hypercholesterolemia due to a known pathogenic APOB gene variant, c.10580 G>A: p.(Arg3527Gln).

J Clin Lipidol. 2020

[2]
Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.

J Am Coll Cardiol. 2020-5-26

[3]
ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand.

J Clin Lipidol. 2020

[4]
Cascade screening for familial hypercholesterolemia-identification of the C308Y mutation in multiple family members and relatives for the first time in mainland China.

BMC Med Genet. 2019-11-9

[5]
Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients.

Atherosclerosis. 2019-8-19

[6]
Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials.

J Clin Lipidol. 2019-6-27

[7]
Current Status of Familial Hypercholesterolemia in China: A Need for Patient FH Registry Systems.

Front Physiol. 2019-3-20

[8]
A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab.

J Chin Med Assoc. 2019-4

[9]
Genetic variations in familial hypercholesterolemia and cascade screening in East Asians.

Mol Genet Genomic Med. 2019-2

[10]
Application of expanded genetic analysis in the diagnosis of familial hypercholesterolemia in patients with very early-onset coronary artery disease.

J Transl Med. 2018-12-10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索